{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:48:55Z","timestamp":1780058935638,"version":"3.54.0"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Psoriasis is an immune-mediated inflammatory skin disease. Although biologics have markedly improved psoriasis symptoms, they may occasionally trigger paradoxical inflammatory reactions, particularly with IL-17A or TNF-\u03b1 inhibitors. However, paradoxical inflammatory reactions associated with the IL-23 inhibitor guselkumab is exceptionally rare. We describe the case of a 70-year-old male with a 5-year history of psoriasis who had previously received tofacitinib for one year without achieving complete clearance. Following the initiation of guselkumab, the patient developed paradoxical eczema. Subsequent treatment with cyclosporine and the TYK2 inhibitor deucravacitinib proved ineffective. Ultimately, combination therapy with the JAK1 inhibitor upadacitinib and the PDE4 inhibitor apremilast achieved satisfactory control of both the paradoxical eczema and the underlying psoriatic lesions. This case highlights that upadacitinib used in combination with apremilast can effectively reverse paradoxical inflammatory reactions while sustaining psoriasis control. This dual-targeting strategy offers a novel therapeutic option for biologic-induced paradoxical reactions, and its broad-spectrum anti-inflammatory properties and potential synergistic effects warrant further clinical investigation.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1696255","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:22:19Z","timestamp":1776403339000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Upadacitinib and apremilast combination therapy for guselkumab-induced paradoxical eczema in psoriasis"],"prefix":"10.3389","volume":"17","author":[{"given":"Luan","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Jinan Dermatosis Prevention and Control Hospital","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Jinan Dermatosis Prevention and Control Hospital","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenqiang","family":"Ruan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Jinan Dermatosis Prevention and Control Hospital","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshi","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Jinan Dermatosis Prevention and Control Hospital","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.adengl.2018.09.012","article-title":"Paradoxical reactions to biologic therapy in psoriasis: a review of the literature","volume":"109","author":"Munera-Campos","year":"2018","journal-title":"Actas Dermosifiliogr Engl Ed"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.09.005","article-title":"Eczematous eruption after guselkumab treatment for psoriasis","volume":"5","author":"Reyn","year":"2019","journal-title":"JAAD Case Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.4846","article-title":"Risk of paradoxical eczema in patients receiving biologics for psoriasis","volume":"160","author":"Al-Janabi","year":"2024","journal-title":"JAMA Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/der.0000000000000765","article-title":"Anti-interleukin 23-based therapies may shift cutaneous immune responses: a case of new-onset contact dermatitis to carbamates after guselkumab for psoriasis","volume":"32","author":"Liakos","year":"2021","journal-title":"Dermatitis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16246","article-title":"Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review","volume":"34","author":"Al-Janabi","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20857","article-title":"Eczematous reaction to guselkumab successfully treated with upadacitinib","volume":"40","author":"Moreno-Davila","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.22541\/au.161718382.20133527\/v1","article-title":"Hypersensitivity reactions to biologicals: an EAACI position paper","volume":"77","author":"Bavbek","year":"2022","journal-title":"Allergy"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2147\/jir.s380686","article-title":"TYK2 in immune responses and treatment of psoriasis","volume":"15","author":"Shang","year":"2022","journal-title":"J Inflammation Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: mechanism of action, clinical, and translational science","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin Transl Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2018.1512404","article-title":"Tofacitinib for the treatment of psoriasis and psoriatic arthritis","volume":"14","author":"Berekmeri","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2023.4489","article-title":"Response to upadacitinib in a patient with palmoplantar psoriasis","volume":"33","author":"Martinez-Molina","year":"2023","journal-title":"Eur J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.20944\/preprints202412.1339.v1","article-title":"Exploring the therapeutic landscape: a narrative review on topical and oral phosphodiesterase-4 inhibitors in dermatology","volume":"17","author":"Carmona-Rocha","year":"2025","journal-title":"Pharmaceutics"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1696255\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:22:23Z","timestamp":1776403343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1696255\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":12,"alternative-id":["10.3389\/fimmu.2026.1696255"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1696255","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"article-number":"1696255"}}